Preliminary Thinking on the Establishment of Pharmacovigilance System in China

doi:10.19803/j.1672-8629.2020.11.01

Abstract

Abstract: The new Drug Administration Law required the establishment of pharmacovigilance system in China. In this paper, the origin and development of pharmacovigilance concept were reviewed, the pharmacovigilance system and its applicability were discussed from the perspective of drug regulatory concept reform, and the concerned problems in the establishment of pharmacovigilance system were put forward.

Key words: drug administration law, pharmacovigilance, adverse drug reaction monitoring, drug supervision

CLC Number:

R951

YUAN Lin, GAOYan, LU Changfei. Preliminary Thinking on the Establishment of Pharmacovigilance System in China[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 749-752.

References

[1] The Sixth National People's Congress. Drug Administration Law of the People's Republic of China[EB/OL].(2019-08-26)[2020-05-20]. https://baike.so.com/doc/4532344-4742546.html.
[2] Peng Lili, WANG Dang, et al.Shen Lu.Development and Origin of Pharmacovigilance[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2016,13(7):410-413.
[3] WHO. Report of a WHO Meeting.International Drugmonitoring: The Role of National centres[EB/OL]. [2019-10-10]. https://www.who-umc.org/media/2680/who-technical-report-498.pdf,1972.
[4] Springer Vienna.WHO collaborating centre for international drug monitoring[J]. Dictionary of Pharmacertical Medicine, 2009, 1534(1):193-193.
[5] Gao Ya, An Hong, Xu Minhao, et al.Brief introduction of Chinese medicine pharmacovigilance[J].Joural of Basic Chinese Medicine(中国中医基础医学杂志),2019, 25(2):233-234.
[6] Zhou Yi, Chen Gang, Zhang Xinyu, et al.The Toxicity Theory of Traditional Chinese Medicine in "Huangdi Neijing"[J].Sichuan Traditional Chinese Medicine(四川中医), 2009,27(3):33-34.
[7] Kong Zengke.A masterpiece on the adverse reactions of traditional Chinese medicine-"Materia Medica"[C]. The 14th National Conference on the History of Pharmacy and Materia Medica,2007:21-212.
[8] National Medical Products Administration. Announcement on Direct Reporting of Adverse Reactions by Drug Marketing License Holders [EB/OL].(2018-10-01)[2020-05-20].https://www.nmpa.gov.cn/.
[9] The General Office of the Central Committee of the Communist Party of China and the General Office of the State Council issued the "Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices"[EB/OL].(2017-10-08)[2020-05-20]. http://www.gov.cn/zhengce/2017-10/08/content_5230105.htm.
[10] Shi Jingjing.Implementing the "four strictest" to ensure drug safety-Interpretation of the new version of "The People's Republic of China Drug Administration Law"[J]. China Quality and Technical Supervision(中国质量技术监管), 2019(9):22-23.
[11] Yu Jinran, Wang Hongwei, Wang Yifang, et al.Research and Enlightenment on the Life Cycle Management of Drug Labeling in the United States[J]. Chinese Journal Pharmacovigilance(中国药物警戒), 2018, 15(6): 333-338.
[12] Song Chunyan, Wang Xiaoning, Xin Lei.Innovative drug supervision methods to create a new pattern of smart supervision[J]. China Food and Drug Administration(中国食品药品监管), 2020(3):54-59.
[13] Liu Xiaoqing, Sun Xiaochuan. The US FDA released the "Real World Evidence Program Framework" [EB/OL]. (2018-12-09) [2020-05-20]. https://www.medsci.cn/article/show_article.do?id=32cb1554e8e4.

[1]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[2]	XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
[3]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[4]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[5]	SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
[6]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[7]	ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan. Comparison standard terminology for pharmaceutical dose forms [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
[8]	LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping. Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
[9]	HUO Peiqiong, ZHENG Peng, SU Zhenhao. Pharmacovigilance in retail pharmacies for special or major diseases [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
[10]	YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing. Safety of sugammadex for reversal of neuromuscular block based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
[11]	PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263.
[12]	JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094.
[13]	WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong. Current applications of artificial intelligence in pharmacovigilance in the USA and implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
[14]	ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia. Thyroid immune-related adverse reactions of immune checkpoint inhibitors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.
[15]	JIANG Hao, ZHANG Bing, ZHANG Xiaomeng, LIN Zhijian, LYU Jintao, ZHANG Dan. Descriptions of pharmacovigilance in materia medica works of Sui, Tang and the Five Dynasties [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 987-993.